biote (BTMD) Competitors $3.87 -0.11 (-2.76%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$3.73 -0.14 (-3.62%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. ARDX, ZYME, LENZ, CVAC, CRMD, CMRX, CDMO, CRON, PRAX, and NRIXShould you be buying biote stock or one of its competitors? The main competitors of biote include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), Praxis Precision Medicines (PRAX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. biote vs. Ardelyx Zymeworks LENZ Therapeutics CureVac CorMedix Chimerix Avid Bioservices Cronos Group Praxis Precision Medicines Nurix Therapeutics Ardelyx (NASDAQ:ARDX) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Which has stronger earnings and valuation, ARDX or BTMD? biote has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$361.71M2.64-$39.14M-$0.22-18.14biote$199.38M1.06$3.32M$0.616.34 Do institutionals and insiders hold more shares of ARDX or BTMD? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 4.8% of Ardelyx shares are held by company insiders. Comparatively, 24.0% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ARDX or BTMD more profitable? biote has a net margin of 5.20% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat biote's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-11.73% -24.87% -10.51% biote 5.20%-32.41%22.26% Does the media prefer ARDX or BTMD? In the previous week, Ardelyx had 12 more articles in the media than biote. MarketBeat recorded 12 mentions for Ardelyx and 0 mentions for biote. Ardelyx's average media sentiment score of 0.85 beat biote's score of 0.20 indicating that Ardelyx is being referred to more favorably in the media. Company Overall Sentiment Ardelyx Positive biote Neutral Does the MarketBeat Community prefer ARDX or BTMD? Ardelyx received 524 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 67.46% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformArdelyxOutperform Votes53967.46% Underperform Votes26032.54% bioteOutperform Votes15100.00% Underperform VotesNo Votes Which has more risk & volatility, ARDX or BTMD? Ardelyx has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, biote has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Do analysts recommend ARDX or BTMD? Ardelyx presently has a consensus target price of $10.39, indicating a potential upside of 160.37%. biote has a consensus target price of $8.00, indicating a potential upside of 106.72%. Given Ardelyx's higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90biote 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryArdelyx beats biote on 10 of the 19 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.73M$1.16B$5.38B$8.39BDividend YieldN/AN/A5.21%4.10%P/E Ratio14.8810.4326.8019.71Price / Sales1.068.64389.55117.28Price / Cash9.6010.4038.2534.62Price / Book-6.671.486.804.50Net Income$3.32M-$54.34M$3.23B$248.18M7 Day Performance-3.73%2.12%1.53%0.23%1 Month Performance11.21%9.10%10.05%12.39%1 Year Performance-33.62%-35.75%16.75%7.07% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.8191 of 5 stars$3.87-2.8%$8.00+106.7%-30.5%$211.73M$199.38M14.88194ARDXArdelyx4.4962 of 5 stars$3.53-2.5%$10.39+194.3%-48.3%$844.57M$361.71M-22.0690Insider TradeZYMEZymeworks3.3659 of 5 stars$12.02+6.3%$21.00+74.7%+34.0%$836.32M$76.30M-8.01460News CoveragePositive NewsAnalyst ForecastInsider TradeLENZLENZ Therapeutics1.8429 of 5 stars$29.37+11.5%$46.60+58.7%+51.1%$826.65MN/A-16.59110Gap UpCVACCureVac3.7165 of 5 stars$3.62+4.3%$14.00+286.7%+18.5%$812.10M$535.18M6.58880News CoverageGap DownCRMDCorMedix2.1039 of 5 stars$11.86+1.7%$15.00+26.5%+141.9%$804.40M$82.55M-14.6430CMRXChimerix0.558 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990CDMOAvid Bioservices0.8059 of 5 stars$12.50+0.1%$12.25-2.0%+37.6%$799.18M$139.91M-5.23320High Trading VolumeCRONCronos Group1.0097 of 5 stars$2.05+3.5%$3.50+70.7%-25.3%$790.08M$117.62M-15.77450Positive NewsHigh Trading VolumePRAXPraxis Precision Medicines3.1671 of 5 stars$38.42+0.2%$116.50+203.2%-15.8%$782.58M$8.12M-3.73110Gap UpNRIXNurix Therapeutics2.4174 of 5 stars$10.18+7.2%$30.44+199.1%-38.6%$776.08M$56.42M-3.52300Positive NewsGap Up Related Companies and Tools Related Companies Ardelyx Alternatives Zymeworks Alternatives LENZ Therapeutics Alternatives CureVac Alternatives CorMedix Alternatives Chimerix Alternatives Avid Bioservices Alternatives Cronos Group Alternatives Praxis Precision Medicines Alternatives Nurix Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
